[Selective bladder sparing with transrectal resection of muscle-infiltrating tumors].
OBJECTIVE
To disclose te ability of TUR as monotherapy in muscle invasive bladder cancer.


METHODS
27 patients with muscle-invasive bladder cancer recruited throughout 1991-1999 were allocated into a protocol based on TUR. 30-45 days after the first TUR a second procedure was performed. The number of recurrences and progressions was registered. Progression-free survival and survival were analyzed using Kaplan-Meier estimates.


RESULTS
Two patients were excluded due to persistence of muscle-invasive disease after the second resection. 8 subjects (32%) were lost in follow-up. 17 were eventually evaluable. 12 patients (70.5%) had recurrences. Eventually, 4 more cystectomies were undertaken for invasive recurrences (4/17, 23.5%). During the study period, 3 deaths were recorder (3/17, 17.6%). The actuarial probability of progression at 93 months was estimated on 60%.


CONCLUSIONS
75% of patients retained their bladders. The proportion of patients lost in follow-up was very high. Patients must commit to a close surveillance.
Páez Borda
A
A
Servicio de Urología, Hospital Universitario de Getafe, Madrid.
Luján Galán
M
M
Romero Cajigal
I
I
Llanes González
L
L
Gómez de Vicente
J M
JM
Berenguer Sánchez
A
A
D000368:Aged; D015653:Cystectomy / Q000379:methods*; D006801:Humans; D009130:Muscle, Smooth / Q000601:surgery; D011446:Prospective Studies; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000601:surgery*